Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Multiple fresh animal-health catalysts: on 2026-05-06 Elanco raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; on 2026-06-15 USDA approved TruCan Ultra Lyme-L4 with shipping expected within 30 days; Q1 2026 margins and profitability improved, supporting a constructive short-term setup.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Margin Expansion ā¢ High Leverage ā¢ Cash Volatility ELAN's fundamentals are improving with strong gross margins, recent operating profit and solid liquidity, but high debt, heavy intangibles, inconsistent cash flow and a still-rich valuation keep the risk/reward balanced.
Price Behavior
Key Price Behavior Insights: ā¢ Higher lows ā¢ Held support ā¢ Near resistance Support Level: $24.60-$24.70 Resistance Level: $25.95-$26.00 ELAN has climbed about 7% over the last month, staying above $24.60 support with improving higher lows, but momentum may stall unless it breaks $25.95-$26.00 resistance.
Sentiment & News
Key News Insights: ā¢ Options activity ā¢ Earnings date ā¢ Beat potential ELAN is drawing increased investor attention ahead of its 2026-08-05 Q2 earnings report, with options activity and its history of earnings beats fueling expectations for a potential upside surprise.
AI Summary
ELAN has evolved from a leveraged turnaround into a genuine execution story, but with ~3.5x net leverage, weak free cash flow, and a valuation already pricing in success, the key takeaway is that upside now depends on proving new product growth can translate into sustained cash generation and faster deleveraging.
Description
Elanco Animal Health Inc. develops, manufactures and markets pharmaceuticals, vaccines and nutritional health products for companion animals and food-producing species, including treatments for parasites, infectious disease and common chronic conditions. The company distributes through third-party distributors, veterinarians and farm producers across beef, dairy, pork, poultry and aquaculture markets; it was founded in 1954 and is headquartered in Greenfield, Indiana.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 24 | Jul 1 | ELAN | Elanco Animal Health Incorporated | Multiple fresh animal-health catalysts: on 2026-05-06 Elanco raised full-year 2026 revenue, adjusted EBITDA, and adjusted EPS guidance; on 2026-06-15 USDA approved TruCan Ultra Lyme-L4 with shipping expected within 30 days; Q1 2026 margins and profitability improved, supporting a constructive short-term setup. | Closed | +0.5% |
| Jun 12 | Jun 19 | ELAN | Elanco Animal Health Incorporated | Animal-health guidance raise with product catalysts: Q1 2026 revenue grew 15% YoY to $1.371B, management raised 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and innovation revenue, while new launches such as Advantage Collar for Dogs and Befrena support near-term sentiment. Stock is up about 12% over 21 trading days. | Closed | +0.2% |
| Jun 5 | Jun 12 | ELAN | Elanco Animal Health Incorporated | Animal-health recovery with concrete catalysts: Q1 2026 revenue grew 15% YoY to $1.371B and management raised full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and year-end leverage. New products including Befrena and Advantage Collar plus the New World screwworm backdrop add timely sector support. | Closed | +2.3% |